Sulfadiazine silver 1% cream
Requires a prescription from a doctor or prescriber
Silver sulfadiazine is a sulfa derivative topical antibacterial used primarily on second- and third-degree burns.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Sulfadiazine silver
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
4 branded products available
MHRA licensed products
View all licensed products for Sulfadiazine silver on the MHRA register
Flamazine 1% cream
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(2)
Leg ulcer infection: antimicrobial prescribing (NG152)
Prontosan for treating acute and chronic wounds (HTG616)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 28 studies.
Reviews & meta-analyses: 4 · 2001–2026
Showing all 28 studies, sorted by most relevant.
Heloisa Helena Nímia, V. F. Carvalho, Cesár Isaac, et al.
Burns : journal of the International Society for Burn Injuries, 2019
- Bandages
- Wound Healing
- Anti-Infective Agents, Local
Danladi Makeri, Martin Odoki, Emmanuel Eilu, et al.
Bulletin of the National Research Centre, 2023
Abstract Background Diabetes mellitus is increasing in Africa, and diabetes-related amputations exacerbated by diabetic foot infection are also prevalent with Staphylococcus aureus and Pseudomonas aeruginosa two priority pathogens playing key roles. Understanding the local epidemiology and antimicrobial resistance profiles of these dominant pathogens is crucial for appropriate antibiotic therapy. Main body of abstract This systematic review and meta-analysis aim to contribute valuable insights that can guide the management of diabetic foot ulcer-related infections in Africa by comprehensively analyzing the available literature on the prevalence and antimicrobial resistance profiles of Staphylococcus aureus and Pseudomonas aeruginosa in infected diabetic foot ulcers across Africa. We conducted a continent-based literature search utilizing PubMed and Scopus databases on June 11th, 2023, to identify studies conducted in Africa among persons with diabetic foot ulcers that reported isolating bacteria from the foot ulcers. The main concepts related to this research, “diabetic foot ulcers”, “diabetic foot infections”, “bacteria” and “Africa” were expanded with their synonyms and combined using Boolean operators (AND, OR) to formulate the final search query. The selection and inclusion of studies followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA). Our review revealed that approximately 4124 bacteria have been isolated from diabetic foot ulcers across 13 African countries. Staphylococcus aureus is the dominant species with a random effect pooled prevalence of 19.9% (95%CI: [16.19–23.84%]; I 2 = 88.56% [82.26–92.62%]) followed by Pseudomonas aeruginosa with 11.8% (95%CI: [8.67–15.23%]; I 2 = 89.95% [84.67–93.41%]). Methicillin-resistant Staphylococcus aureus (MRSA) pooled 12.9% (95%CI: [3.99–25.89%]; I 2 = 95.47% [93.68–96.75%]). Multidrug-resistant S.aureus and P. aeruginosa pooled prevalence is 26.4% (95%CI: [17.84–36.06%]; I 2 = 71.16% [49.34–83.58%]) and 41.8% (95%CI: [27.38–56.91%]; I 2 = 78.48% [60.80–88.18%]), respectively. Short conclusion Staphylococcus aureus dominates diabetic foot ulcer (DFU) isolates in Africa contrary to the prevailing assertion about Pseudomonas aeruginosa . However, multidrug resistance among both species is high emphasizing the need for antimicrobial stewardship and utilization of other wound management protocols such as topical silver sulfadiazine (SSD) for the duo.
Abstract licence: CC BY
N. Levin, Young Erben, Yupeng Li, et al.
Cureus, 2022
Burn wounds remain a prevalent problem in the developed and developing world. A multitude of remedies has been tested. This study evaluated the healing time of second- and third-degree burn wounds between silver sulfadiazine (SSD) and Aloe vera (AV). In July 2020, a systematic review of MEDLINE (Ovid) and PubMed (National Library of Medicine) was performed to identify studies that reported healing of second- and third-degree burns using either SSD or AV. Articles meeting the inclusion criteria were screened and carefully analyzed. Our goal was to report the healing time for these burns using SSD and AV. A total of eight studies published between 1988 and 2018 reporting healing of second- and third-degree burns using SSD and AV were included in this review. Six were cohort studies and two were randomized controlled trials. The studies included both animal and human subjects. The meta-analysis demonstrated that the mean time to wound healing favored AV (RR: -1.34, 95% CI: -1.8 to 0.9, p < 0.001). It would seem that time to healing benefitted those burns in which AV was utilized. In conclusion, increased consideration and emphasis should be placed on using AV to aid the healing of second- and third-degree burns.
Abstract licence: CC BY
Harshita Abul Barkat, Md Abul Barkat, Raisuddin Ali, et al.
The International Journal of Lower Extremity Wounds, 2023
- Anti-Infective Agents, Local
- Burns
- Silver Sulfadiazine
Shahram Ahmadian, Marjan Ghorbani, F. Mahmoodzadeh
International journal of biological macromolecules, 2020
- Anti-Infective Agents, Local
- Anti-Bacterial Agents
- Cellulose
C. Bergonzi, Annalisa Bianchera, Giulia Remaggi, et al.
Micromachines, 2023
The growing demand for personalized medicine requires innovation in drug manufacturing to combine versatility with automation. Here, three-dimensional (3D) printing was explored for the production of chitosan (CH)/alginate (ALG)-based hydrogels intended as active dressings for wound healing. ALG hydrogels were loaded with 0.75% w/v silver sulfadiazine (SSD), selected as a drug model commonly used for the therapeutic treatment of infected burn wounds, and four different 3D CH/ALG architectures were designed to modulate the release of this active compound. CH/ALG constructs were characterized by their water content, elasticity and porosity. ALG hydrogels (Young’s modulus 0.582 ± 0.019 Mpa) were statistically different in terms of elasticity compared to CH (Young’s modulus 0.365 ± 0.015 Mpa) but very similar in terms of swelling properties (water content in ALG: 93.18 ± 0.88% and in CH: 92.76 ± 1.17%). In vitro SSD release tests were performed by using vertical diffusion Franz cells, and statistically significant different behaviors in terms of the amount and kinetics of drugs released were observed as a function of the construct. Moreover, strong antimicrobial potency (100% of growth inhibition) against Staphylococcus aureus and Pseudomonas aeruginosa was demonstrated depending on the type of construct, offering a proof of concept that 3D printing techniques could be efficiently applied to the production of hydrogels for controlled drug delivery.
Abstract licence: CC BY
Jie Zhou, Tianjiao Li, Meili Zhang, et al.
Journal of Nanobiotechnology, 2023
- Silver Sulfadiazine
- Hydrogels
- Anti-Bacterial Agents
Wounds can lead to skin and soft tissue damage and their improper management may lead to the growth of pathogenic bacteria at the site of injury. Identifying better ways to promote wound healing is a major unmet need and biomedical materials with the ability to promote wound healing are urgently needed. Here, we report a thermosensitive black phosphorus hydrogel composed of black phosphorus nano-loaded drug silver sulfadiazine (SSD) and chitosan thermosensitive hydrogel for wound healing. The hydrogel has temperature-sensitive properties and enables the continuous release of SSD under near-infrared irradiation to achieve synergistic photothermal and antibacterial treatment. Additionally, it exerts antibacterial effects on Staphylococcus aureus. In a rat skin injury model, it promotes collagen deposition, boosts neovascularization, and suppresses inflammatory markers. In summary, the excellent thermosensitivity, biocompatibility, and wound-healing-promoting qualities of the reported thermosensitive hydrogel make it suitable as an ideal wound dressing in the clinic.
Abstract licence: CC BY
Julia H Bormio Nunes, Douglas Hideki Nakahata, P. Corbi, et al.
Coordination Chemistry Reviews, 2023
M. Khan, Davood Kharaghani, Sanaullah, et al.
Polymer Testing, 2019
M. Mohseni, A. Shamloo, Zahra Aghababaie, et al.
International journal of pharmaceutics, 2019
- Bandages
- Anti-Bacterial Agents
- Cell Survival
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Studies utilizing radioactive micronized silver sulfadiazine, electron microscop…
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 55 interactions
Silver binds to surface membranes and proteins, causing proton leaks in the membrane, leading to cell death.
Sulfadiazine is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
How the body processes this drug — absorption, distribution, metabolism, and elimination
ATC D06BA01
ATC G01AE10
ATC D06BA51
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Additional database identifiers
Drugs Product Database (DPD)
8195
ChemSpider
390017
GenBank Gene Database
X68776
GenBank Protein Database
41273
UniProt Accession
DHPS_ECOLI
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q420984), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.